Gilde Healthcare, an Utrecht, The Netherlands-based healthcare focused private equity firm, closed Gilde Healthcare Private Equity IV, at €517m.
The fund, which received the support from institutional investors from the Netherlands, Germany, United Kingdom, France, Italy, and Scandinavia, will make investments in healthcare companies in the lower mid-market in Northwest Europe.
The fund concentrates on firms with an active buy-and-build strategy and invests in all sub-segments of the healthcare sector. These include companies in healthcare provision, service providers to the healthcare sector and medical industry, manufacturers of medical supplies and pharmaceutical companies.
The Gilde Healthcare Private Equity IV fund targets companies with an EBITDA of €2 to €15 million.
Recent examples of private equity investments in healthcare include among others the buy-and-builds of Dutch ACE Pharmaceuticals, German cannula manufacturer Acti-Med, Danish clinical research organization Klifo and Dutch contract research organization Symeres, which was recently sold.
Led by Jasper van Gorp, Managing Partner and Head of the Private Equity team, the firm’s investment team consists of experienced sector experts who have made investments in all segments of the healthcare industry over the past 20 years.
In combination with its vintage 2020 transatlantic Venture&Growth fund V, Gilde Healthcare has raised €933 million ($1.0 billion) in capital in less than two years. Since its foundation in 2006, the firm has made 70 platform investments, of which 46 have been sold or floated.
FinSMEs
16/03/2022